Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human LPAR1 Antibodies:
anti-Mouse (Murine) LPAR1 Antibodies:
anti-Rat (Rattus) LPAR1 Antibodies:
Go to our pre-filtered search.
Chicken Polyclonal LPAR1 Primary Antibody for ICC, IF - ABIN315888
Park, Kazlauskas: Primary human endothelial cells secrete agents that reduce responsiveness to lysophosphatidic acid (LPA). in Bioscience reports 2012
Show all 3 Pubmed References
Human Polyclonal LPAR1 Primary Antibody for IHC (p) - ABIN270785
Horak, Mendoza, Vega-Valle, Albaugh, Graff-Cherry, McDermott, Hua, Merino, Steinberg, Khanna, Steeg: Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. in Cancer research 2007
Show all 2 Pubmed References
Human Polyclonal LPAR1 Primary Antibody for IF (p), IHC (p) - ABIN681103
Chen, Zhang, Deng, Liu, Yang, Wu, Yu: Lysophosphatidic acid directly induces macrophage-derived foam cell formation by blocking the expression of SRBI. in Biochemical and biophysical research communications 2017
Human Polyclonal LPAR1 Primary Antibody for ICC, IF - ABIN314557
Sokolov, Eheim, Ahrens, Walling, Swet, McMillan, Simo, Thompson, Sindram, McKillop: Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma. in The Journal of surgical research 2013
Bat Polyclonal LPAR1 Primary Antibody for IHC (p) - ABIN4331400
Ward, Lake, Yin, Heger, Raffeld, Goldsmith, Merino, Kelly: LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. in Cancer research 2011
ATX (show ENPP2 Antibodies)-LPA (show APOA Antibodies) axis facilitates estrogen-induced endometrial cancer cell proliferation via MAPK/ERK (show MAPK1 Antibodies) signaling pathway.
DLD (show DLD Antibodies)-C-F cells formed large-sized colonies, but not DLD (show DLD Antibodies)-F-C cells, correlating with LPAR1 and LPAR6 (show LPAR6 Antibodies) gene expression levels. These results suggest that LPA1 and LPA6 (show LPAR6 Antibodies) may regulate the colony formation activity in DLD1 cells treated with anticancer drugs.
endogenous LPA1 receptor signaling and regulation
The increased expression of LPA (show APOA Antibodies) and LPAR1 is associated with the fibrosis and hypertrophy of the ligamentum flavum in patients with Lumbar Spinal Stenosis.
myeloma cells stimulate mesenchymal stem cells (MSCs to produce autotaxin (show ENPP2 Antibodies), an indispensable enzyme for the biosynthesis of lysophosphatidic acid, and LPA receptor 1 (LPA1) and 3 (LPA3 (show LPAR3 Antibodies)) transduce opposite signals to MSCs to determine the fate of MSCs.
LPA1 plays a critical role in EGF (show EGF Antibodies) responses and that FFA4 agonists inhibit proliferation by suppressing positive cross-talk between LPA1 and the EGF receptor (show EGFR Antibodies)
ADAMTS7 (show ADAMTS7 Antibodies) and LPA (show APOA Antibodies) single nucleotide polymorphisms are related to a 24-h ambulatory systolic-diastolic pressure regression index.
Polymorphism rs7023923 located near LPAR1 gene: the association of rs7023923 with monocytosis was confirmed among healthy blood donors (p = 0.0156) but not among patients admitted for elective coronarography (p = 0.61).
These results suggest that autotaxin (show ENPP2 Antibodies)-LPA-LPA (show APOA Antibodies) receptor 1-AKT1 (show AKT1 Antibodies) signaling axis is critical for maintaining Cancer stem cells(CSC) characteristics through an autocrine loop and provide a novel therapeutic target for ovarian CSCs
LPA (show APOA Antibodies)-type agonist, via Carbonyl-oxygen/Lys39 interaction facilitates the formation of a hypothetical N-terminal cap tightly packed over the LPA1 heptahelical bundle.
Study shows that lysophosphatidic acid (LPA (show LPA Antibodies)) propagates post-injury schwann cell (SC) dedifferentiation through lysophosphatidic acid 1 signaling. These data indicate that LPA (show LPA Antibodies) may be a critical factor that shifts SCs (show TWIST1 Antibodies) towards a post-injury phenotype and contributes to the onset of Wallerian degeneration.
we demonstrate that LPA1/3 antagonism mildly reduced plasma LDL cholesterol levels. Therefore, pharmacological inhibition of LPA1/3 receptors may prove a promising approach to diminish atherosclerosis development.
LPA receptor 1 signaling increased TGFbeta (show TGFB1 Antibodies) expression via GSK3beta phosphorylation and SREBP1 (show SREBF1 Antibodies) activation, contributing to the development of diabetic nephropathy.
Our data suggest that LPAR signaling stimulates SS development by induction of IL-17 (show IL17A Antibodies) production via ROCK and p38 MAPK (show MAPK14 Antibodies) pathways. Thus, LPAR inhibition could be a possible therapeutic strategy for SS.
LPA (show LPA Antibodies)-LPA1 signaling initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor (show CTGF Antibodies).
Data (including data from studies conducted in cells from knockout mice) suggest that signaling via Lpar1, Cd14 (show CD14 Antibodies), and Scara1 (show MSR1 Antibodies) mediates uptake of oxidized LDL by macrophages leading to foam cell formation; lysophosphatidic acid (LPA (show LPA Antibodies)) induces expression of Cd14 (show CD14 Antibodies) and Scara1 (show MSR1 Antibodies) in macrophages. (Lpar1 = LPA receptor 1; Cd14 (show CD14 Antibodies) = monocyte differentiation antigen CD14 (show CD14 Antibodies); Scara1 (show MSR1 Antibodies) = scavenger receptor class A type I)
Our results suggest that LPA (show LPA Antibodies)-enhanced foam cell formation is mediated by LPA1/3 -AKT (show AKT1 Antibodies) activation and subsequent SRBI (show SCARB1 Antibodies) expression.
Lysophosphatidic acid-LPA1 signaling is critically required for septation during alveolarization.
Data show that lysophosphatidic acid receptor 1 (LPA1)-green fluorescent proteins can be used to directly quantify the running-induced increase in precursor proliferation.
Results suggest a relevant role for the Lysophosphatidic acid/Lysophosphatidic acid receptor 1 signaling system in alcoholism. In addition, the LPA1-null mice emerge as a new model for genetic vulnerability to excessive alcohol drinking
Lysophosphatidic acid stimulates PGE (show LIPF Antibodies)(2) production, cell viability, and intracellular calcium ion mobilization in cultured stromal endometrial cells via Ki16425-sensitive LPA1 receptors.
the ATX (show ENPP2 Antibodies)-LPA (show LPA Antibodies)-LPAR axis is a critical regulator of embryonic vascular development that is conserved in vertebrates
LPA(1) is necessary for lymphatic vessel formation during embryonic development in zebrafish.
The integral membrane protein encoded by this gene is a lysophosphatidic acid (LPA) receptor from a group known as EDG receptors. These receptors are members of the G protein-coupled receptor superfamily. Utilized by LPA for cell signaling, EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion. Two transcript variants encoding the same protein have been identified for this gene
endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2
, lysophosphatidic acid receptor 1
, lysophosphatidic acid receptor 1-like
, LPA receptor 1
, lysophosphatidic acid receptor Edg-2
, ventricular zone gene 1
, G-protein coupled receptor 26
, clone 4.9
, endothelial differentiation lysophosphatidic acid G-protein-coupled receptor 2
, endothelium differentiation gene 2